男子非淋菌性尿道炎の治療学的研究

Abstract

非淋菌性尿道炎症例に対し, AT-2266 1日600 mg 7日間投与し, その治療成績の検討とともにそれら症例の各種背景因子の詳細な分析も合わせて行なった.1)非淋菌性尿道炎症例106例の年齢分布は10歳代後半から30歳代前半にかけて症例が多く15歳～19歳が11.3%にもなっている.2)感染源は歓楽街女性:素人女性の比が37:53と素人女性が多く, 淋菌感染症のそれと逆転していた.3)尿道分泌物培養で得られた分離菌は, ほとんどがGPCことにS. epidermidisであったが, 全症例の51.6%は菌陰性であった.4)尿道分泌物の性状は膿性のものが51.9%, 漿性のものが48.1%に見られた.5) AT-2266 1日600 mg(分3服用)7日間投与による有効率は膿性分泌物例群では, 3日間及び7日間治療で有効率それぞれ24.3%, 61.1%であり, 漿性分泌物例群ではそれぞれ, 36.0%, 71.4%であった.6) AT-2266服用による副作用は90例中5例に軽度の胃腸障害を中心として症状発現を見たが, 投与中止の必要なものはなかった

AT-2266 tablets were administered orally in a daily dosage of 600 mg for 7 consecutive days as treatment of non-gonorrheal urethritis in 106 cases. The therapeutic results in 90 cases were investigated, and a detailed analysis of various background factors was also performed. Most of the patients were between 15 and 35 years old; 11.3% of the patients were between 15 and 19 years old. The source of infection was a "professional" woman such as a prostitute in 37 cases, and a non-professional woman in 53 cases. This is noteworthy because the source is more often a "professional" women in the case of gonorrhea. Bacterial isolates were obtained by culture of the urethral secretions. Most were gram-positive cocci, especially S. epidermidis, but, in 51.7% of the patients, no bacteria could be cultured. The urethral secretion was purulent in 51.9% of the patients, and serous in the remaining 48.1%. The efficacy rates obtained when AT-2266 was administered in a daily dosage of 600 mg (in 3 divided oral doses) for 7 days were as follows. In the purulent secretion group, the 3-day and 7-day therapeutic efficacy (elimination of the secretion) rates were 24.2% and 61.2%. In the serous secretion group, the corresponding efficacy rates were 36% and 71.4%. Thus the therapeutic efficacy was slightly inferior in the purulent secretion group. Oral administration of AT-2266 resulted in side effects in 5 of the patients (5.5%). These side effects consisted primarily of mild gastrointestinal disturbances, which did not require discontinued drug administration.